A regulatory data normalization and change-intelligence service that versions public European medicinal-product records, preserves FHIR and source provenance, and proposes reviewed links to United States product sources.
Genesis score7.40/10
Make PharmaCanonEU real.0/500
500 more votes and PharmaCanonEU is authorized for build.
0%500 to authorize
Backing is the vote. When an idea crosses 500, we pull it into the build pipeline and ship it for real — the votes decide what gets built next, not an editor.
The opportunity
Jun 12, 2026Public beta launch
Q4 2026FHIR upgrade planned
0Commercial wrappers found
The case
The official EMA PMS public beta launched two days before the Genesis run and uses FHIR as its base format, creating a genuine first-mover window. No commercial wrapper was identified and a regulatory consultancy explicitly called for readiness. PharmaCanonEU should not call normalized records IDMP-ready or assume European and United States products are equivalent. Its defensible asset is a replayable source history, typed normalization, quality issues, reviewer-approved identity links, and change events whose raw and interpreted layers remain separate.
Who pays — and why
The regulatory-affairs consultancy, medicinal-product data team, IDMP program, safety operation, or software vendor needing traceable European product changes.
What it unlocks
Immutable snapshots of official API responses with endpoint, query, retrieval time, schema, terminology, pagination, deletion, correction, and license provenance
A normalized product model that preserves source identifiers and distinguishes substances, products, authorizations, organizations, packages, documents, countries, languages, and lifecycle state
Field-level change events and candidate cross-source links with evidence, confidence, reviewer decisions, correction history, and subscriber delivery receipts
How Genesis scored it
7.40across seven criteria
8
Productive tension
Fast productization must preserve beta instability, regulatory semantics, source rights, and reviewer-owned identity.
8
Temporal window
The launch occurred immediately before the idea run.
5
Convergence
The record has a strong official trigger but limited independent convergence.
Why it scored well
A brand-new official data source, clear regulatory-data buyer, open technical format, and no identified wrapper support a timely product.
What's holding it back
The source is beta, access and rights can change, cross-source identity is difficult, IDMP readiness is not automatic, and no incumbent barrier is established.
Signals detected5 sources crossed
SignalEMA event research carried in Genesis
SignalEMA technical research carried in Genesis
SignalEMA roadmap research carried in Genesis
SignalAsphalion research carried in Genesis
Signalmarket scan carried in Genesis
Direction briefpharmacanon-eu.md
pharmacanon-eu.md
Want this pointed at your vertical?Point Genesis at your own market and constraints — it invents adjacent, fork-ready ideas, private to you before they hit the public feed.
